Charleston, SC -- (SBWIRE) -- 10/04/2013 -- The Team of advisers at Capital Equity Report are committed to bringing you stock picks that are noteworthy and priced at a great value. We work for you and we welcome any feedback you may have to offer. Have a look at: Sigma Labs Inc (OTCMKTS:SGLB), Bullfrog Gold Corp (OTCMKTS:BFGC), Advanced Cell Technology, Inc. (OTCMKTS:ACTC), Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
Sigma Labs Inc (OTCMKTS:SGLB) decreased -6.60% and closed at $0.0990 on a traded volume of 2.91 million shares, in comparison to 3.33 million shares of average trading volume. So far this year, the stock is up over +560.00%.
The company has a total market capitalization of $54.95 million and its total outstanding shares are 555.02 million. Sigma Labs, Inc. engages in the development and commercialization of manufacturing and materials technologies, and R&D solutions.
Why Should Investors Buy SGLB After the Recent Fall? Just Go Here and Find Out
Bullfrog Gold Corp (OTCMKTS:BFGC) soared +10.71% and closed at $0.310 on a traded volume of 1.63 million shares, whereas its average trading volume is 110,494 shares. In the last three months, the stock is up +55.00%. The Intra-day range for the stock is $0.28 and $0.33.
Bullfrog Gold Corp., a junior exploration company, engages in the acquisition and exploration of gold properties in the United States. It primarily explores for gold and silver ores, as well as zinc, lead, and copper ores.
For How Long BFGC will Fight for Profitability? Read This Trend Analysis report
Advanced Cell Technology, Inc. (OTCMKTS:ACTC) dropped down -0.56% and closed at $0.0708. So far in three months, the stock is down -10.27%. The 52-week range for the stock is $0.05 and $0.10 and during the previous trading session the stock touched its highest price at $0.07. Its introductory price for the day was $0.07, with the overall traded volume of 4.43 million shares.
Advanced Cell Technology, Inc., a biotechnology company, engages in the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine.
Has ACTC Found The Bottom and Ready To Move Up? Find Out Here
Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV), after opening its shares at the price of $1.48, dropped -2.05% to close at $1.43 for the day. The stock moved on a traded volume of 141,754 shares, in comparison to 1.25 million shares of average trading volume.
The 52-week range for the stock is $0.94 and $6.20 and during the previous trading session the stock touched its highest price at $1.53. Its introductory price for the day was $1.48. Invivo Therapeutics Holdings Corp., a development stage company, focuses on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries, peripheral nerve injuries, and other neurotrauma conditions.
Will NVIV Get Buyers Even After The Recent Rally? Find Out Here
Our team of advisers here at Capital Equity Report are committed to bringing you stock picks that are noteworthy and priced at a great value. We work for you and we welcome any feedback you may have to offer.
The disclaimer is to be read and fully understood before using our site, or joining our newsletter email list. Never invest into a stock discussed on this web site or the CapitalEquityReport.com newsletter unless you can afford to lose your entire investment.
Please consult with a certified financial advisor before making any investment decisions.
Read Full Disclaimer at: http://capitalequityreport.com/about-us/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)